Access Pharma: Low Valuation, Big Potential [View article]
In 9/2008 Griffin Securities rated ACCP a "Buy" at $3 with a $14 target after it drifted down from $5.
Then, Griffin again called ACCP a "Buy" at $1.70 (down 43% in TWO months!!), keeping the $14 target.
Now Griffin adjusted the 5/2010 target to $7.50 after it fell another 16.5% in FIVE months.
Technically, this stock is a total LOSER ... an investor's nightmare. Fundamentally, as pumped above and by hapless Griffin, this has the makings of a classic 5-bagger.
But everything I read, including my own portfolio updates, suggests that investors are taking less risk, rather than plunking down cash that odds suggest will evaporate.
Access Pharma: Low Valuation, Big Potential [View article]
Then, Griffin again called ACCP a "Buy" at $1.70 (down 43% in TWO months!!), keeping the $14 target.
Now Griffin adjusted the 5/2010 target to $7.50 after it fell another 16.5% in FIVE months.
Technically, this stock is a total LOSER ... an investor's nightmare. Fundamentally, as pumped above and by hapless Griffin, this has the makings of a classic 5-bagger.
But everything I read, including my own portfolio updates, suggests that investors are taking less risk, rather than plunking down cash that odds suggest will evaporate.
Sorry, Mike: no sale!
Dave